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LETTERS TO THE EDITOR
Antibodies against
macrophages that overlap in
specificity with fibroblasts
To the Editor: In the June issue of Kidney International,
a Technical Note is devoted to the discrimination between
fibroblasts and macrophages in inflamed renal tissue [1].
The authors examined the expression of macrophage
antigens in putative fibroblasts identified by expression
of FSP1. FSP1+ cells expressed macrophage antigens
CD45, Mac-1, Mac-2, Mac-3, CD68, and MHC class II,
but not F4/80. They conclude that among the markers
tested F4/80 is the only one specific for macrophages in
the inflamed mouse kidney since the others are also ex-
pressed in FSP1+ fibroblasts.
We would like to question two assumptions of the
authors.
First, a survey of the literature casts serious doubts on
the specificity of FSP1 (also known as S100A4) for fi-
broblasts. FSP1/S100A4 has been found in various cell
types [2]. Specifically in the kidney, after ureter obstruc-
tion, a fraction of FSP1/S100A4+ cells were identified as
inflammatory cells [3]. In inflamed kidneys we observed
colocalization of FSP1/S100A4 with leukocyte markers in
cells that clearly displayed the morphology of mononu-
clear cells [4].
Second, a subpopulation of dendritic cells expresses
F4/80 [5]. Expression of F4/80 has been demonstrated in
renal dendritic cells [6].
With these facts in mind we propose an interpretation
of the data of Inoue et al [1], which diverge from that of
the authors: At least a fraction of FSP1+ cells in the fi-
brotic kidney are infiltrating leukocytes expressing CD45,
Mac-1, Mac-2, Mac-3, CD68, and MHC class II.
Therefore, the suitability of FSP1 and of F4/80 as mark-
ers for fibroblasts and for macrophages, respectively, must
be questioned.
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Reply from the Authors
We thought our paper in a recent issue of Kidney Inter-
national might stimulate comment on the identification
of macrophages and fibroblasts [1]. Our correspondents
raise two concerns. It is easier to address the second com-
plaint first: our failure to distinguish dendritic cells from
macrophages. This distinction was not our immediate
point. We acknowledge dendritic cells, like macrophages,
have antigen-presenting properties and may be identified
by F4/80 antibodies.
FSP1, or S100A4, is specific for fibroblasts in normal
mice by genetic and protein criteria ([1–3]; reference [7]
in [1]). Our experience in rats is limited, but we have no
reason to feel its specificity is different than mice. Two ex-
periments being readied for publication in human tissue
also support FSP1 specificity in fibroblasts. Nevertheless,
our correspondents’ second criticism cites several publi-
cations that question this specificity.
In one reference, they argue FSP1 is expressed in in-
flammatory cells [3]. Although S100A4 antibody was used
in rat renal tissue, the methods defined stained fibrob-
lasts as “spindle-shaped” cells and stained leukocytes as
“rounded” cells. There was no double-staining to support
this assumption. Some fibroblasts may look ‘round’ de-
pending on their orientation in tissue sections, making a
‘shape’ criterion unreliable.
Our correspondents also assert in their own paper that
FSP1 is expressed by rat leukocytes [4]. Although double-
staining techniques were employed, these authors also
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used ‘cell shape’ to speculate on ‘cell phenotype’ in thin-
sectioned tissues. Unfortunately as well, all antibodies
used, save for anti-FSP1, have well-recognized, multi-
ple specificities—this is the issue we were decrying in
the first place [1]. Briefly, 5′-NT, alpha-smooth muscle
actin, CD45, MHC class II, and Thy1 are found in mul-
tiple cell types, including fibroblasts. CD3 and CD4 are
coexpressed on some T cells with Fcc RIII chains, which
apparently were not blocked during staining. Their pub-
lication does not cover the Mac-series of markers from
our work, nor are they mentioned in their letter, some of
which were originally characterized in fibroblasts (refer-
ence [26] in [1]).
Finally, the correspondents cite a review of S100A4
suggesting FSP1 is expressed in a variety of cells [4].
Space precludes a full response. We agree that FSP1 is
expressed in metastatic tumor cells; these cells reuse the
molecular program of fibroblasts (reference [5] in [1]).
The review also cites the expression of S100A4 in human
monocytes/macrophages and granulocytes (reference
[27] in [4]). The problem is some of these cells were from
a tumor, S100A4 staining of ‘purified’ macrophages or
monocytes was not confirmed with secondary markers, fi-
brocytes circulating in blood were ignored (reference [24]
in [1]), and blood cells were ‘purified’ using adherence to
collagen or gelatin, both of which bind macrophages and
fibroblasts. While our data in mice recognize that a few
hematopoietic precursors in bone marrow briefly express
FSP1 [1], this expression is lost as lineages mature. Other
references in the review citing expression of S100A4 in
skin cells are refuted within the review (reference [29] in
[4]).
In our publication we did not use anti-FSP1 antibody,
but GFP under the control of the FSP1 promoter [1]. This
transgene provides greater sensitivity than antibody de-
tection, and still did not cross-stain with F4/80. We stand
by our work and the work of others not cited who have
reproduced our EMT and fibroblast results with FSP1
as marker. We thank the correspondents for their com-
ments, but feel our original interpretation is the correct
one [1].
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Questions about graft
surveillance
To the Editor: The randomized clinical trial by Malik
et al reported that ultrasound screening for graft stenosis
and preemptive angioplasty resulted in longer arteriove-
nous (A-V) graft patency compared to clinical monitor-
ing alone [1]. Although this appears to be a well-designed
study, the manuscript provides very sketchy details about
the outcomes. We have the following questions for the au-
thors: (1) The paper reports the total frequency of inter-
ventions (angioplasty or thrombectomy) in each group. It
would be very helpful to separate the two. Specifically, did
the overall frequency of angioplasty differ between the
two groups? Did the overall frequency of graft thrombo-
sis differ between the two groups? (2) How many of the
failures in each group were due to irreversible throm-
bosis, and how many due to infection? (3) What pro-
portion of the angioplasties in the ultrasound group was
triggered by abnormal clinical examination, and what
proportion was due to an abnormal ultrasound study?
(4) Did thrombosis-free graft survival differ between the
two study groups?
Two previous randomized clinical trials evaluating ul-
trasound monitoring did not observe an improvement
in graft survival [2, 3]. How do the authors account for
the discrepancy between their study and the previous re-
ports?
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